Skip to main content
Top
Published in: World Journal of Surgery 2/2020

01-02-2020 | Pathology | Original Scientific Report

Need for Completion Thyroidectomy in Patients Undergoing Lobectomy for Indeterminate and High-Risk Nodules: Impact of Intra-Operative Findings and Final Pathology

Authors: Edwina C. Moore, Samuel Zolin, Vikram Krishnamurthy, Judy Jin, Joyce Shin, Eren Berber, Allan Siperstein

Published in: World Journal of Surgery | Issue 2/2020

Login to get access

Abstract

Introduction

Current guidelines increasingly suggest the use of thyroid lobectomy for indeterminate (Bethesda 3 and 4) and high-risk (Bethesda 5 and 6) thyroid nodules; however, the clinical reality is often very different.

Materials and Methods

The aim of this study was to determine the rate of completion thyroidectomy (CTx) for indeterminate and high-risk thyroid nodules which are pre-operatively classified as suitable for unilateral resection (lobe eligible) based on current guidelines. Seven hundred consecutive patients with thyroid nodules and FNA cytology over four years (2015–2018) were reviewed.

Results

Distribution of the dominant nodules by Bethesda was: non-diagnostic 3.9%, benign 28.1%, atypia of unknown significance 19.0%, follicular neoplasm 23.6%, suspicious for malignancy 6.1% and malignancy 19.3%. Of 298 indeterminate nodules, 68.8% (205/298) had relative but independent indications for a total thyroidectomy (TTx) and the remainder were candidates for lobectomy. For these lobe eligible patients, the overall risk of ultimately needing a TTx was 19.4% (18/93), comprising 4.3% (4/93) from intra-operative findings and 15.7% (14/89) from final pathology. Similarly, of 170 high-risk nodules, 63.5% (108/170) had upfront indications for a TTx and the remaining 62 nodules were lobe eligible. Of the patients taken to the operating room for a lobectomy, 21.0% (13/62) were upgraded to a TTx intra-operatively and 26.5% (13/49) post-operatively. The lobe success rate for indeterminate nodules was 25.2% and for high-risk nodules was 21.2%. The rate of CTx, or the proportion of patients needing a second operation was 15.7% (14/89) and 26.5% (13/49), respectively.

Conclusions

In counselling a patient for surgery, the risk of needing a more radical initial procedure or second surgery needs to be accurately explained. There are three points of care that can influence operative strategy, pre-operatively by way of high-risk clinical factors, intra-operatively via anatomical findings and post-operatively in response to unrecognized pathological features. Additionally, the patient’s personal value judgment and level of risk aversion should be taken into consideration.
Literature
2.
go back to reference Murthy SP, Balasubramanian D, Anand A, Limbachiya S, Subrmanian N, Nair V, Thankappan K, Iyer S (2018) Extent of thyroidectomy in differentiated thyroid cancers: review of evidence. Indian J Surg Oncol 9(1):90–96PubMedCrossRef Murthy SP, Balasubramanian D, Anand A, Limbachiya S, Subrmanian N, Nair V, Thankappan K, Iyer S (2018) Extent of thyroidectomy in differentiated thyroid cancers: review of evidence. Indian J Surg Oncol 9(1):90–96PubMedCrossRef
3.
go back to reference Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2015) American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):130–133 Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2015) American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):130–133
4.
go back to reference Carling T, Carty SE, Ciarleglio MM, Cooper DS, Doherty GM, Kim LT, Kloos RT, Massaferri EL, American thyroid Association Surgical Affairs Committee et al (2012) ATA design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid 22(3):237–244PubMedCrossRef Carling T, Carty SE, Ciarleglio MM, Cooper DS, Doherty GM, Kim LT, Kloos RT, Massaferri EL, American thyroid Association Surgical Affairs Committee et al (2012) ATA design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid 22(3):237–244PubMedCrossRef
5.
go back to reference Kluijfhout WP, Pasternak JD, Lim J, Kwon JS, Vriens MR, Clark OH, Shen WT, Gosnell JE, Suh I, Duh QY (2016) Frequency of high-risk characteristics requiring total thyroidectomy for 1–4 cm well-differentiated thyroid cancer. Thyroid 26(6):820–824PubMedCrossRef Kluijfhout WP, Pasternak JD, Lim J, Kwon JS, Vriens MR, Clark OH, Shen WT, Gosnell JE, Suh I, Duh QY (2016) Frequency of high-risk characteristics requiring total thyroidectomy for 1–4 cm well-differentiated thyroid cancer. Thyroid 26(6):820–824PubMedCrossRef
6.
go back to reference Kluijfhout WP, Pasternak JD, Drake FT, Beninato T, Shen WT, Gosnell JE, Suh ICL, Duh QY (2017) Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine. Surgery 161(1):127–133PubMedCrossRef Kluijfhout WP, Pasternak JD, Drake FT, Beninato T, Shen WT, Gosnell JE, Suh ICL, Duh QY (2017) Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine. Surgery 161(1):127–133PubMedCrossRef
7.
go back to reference Lang BH, Shek TW, Wan KY (2017) The significance of unrecognized histological high-risk features on response to therapy in papillary thyroid carcinoma measuring 1–4 cm: implications for completion thyroidectomy following lobectomy. Clin Endocrinol (Oxf) 86(2):236–242CrossRef Lang BH, Shek TW, Wan KY (2017) The significance of unrecognized histological high-risk features on response to therapy in papillary thyroid carcinoma measuring 1–4 cm: implications for completion thyroidectomy following lobectomy. Clin Endocrinol (Oxf) 86(2):236–242CrossRef
8.
go back to reference Dhir M, McCoy KL, Ohori NP, Adkisson CD, LeBeau SO, Carty SE, Yip L (2018) Correct extent of thyroidectomy is poorly predicted preoperatively by the guidelines of the American Thyroid Association for low and intermediate risk thyroid cancers. Surgery 163(1):81–87PubMedCrossRef Dhir M, McCoy KL, Ohori NP, Adkisson CD, LeBeau SO, Carty SE, Yip L (2018) Correct extent of thyroidectomy is poorly predicted preoperatively by the guidelines of the American Thyroid Association for low and intermediate risk thyroid cancers. Surgery 163(1):81–87PubMedCrossRef
9.
go back to reference Cheng SP, Chien MN, Wang TY, Lee JJ, Lee CC, Liu CL (2018) Reconsideration of tumor size threshold for total thyroidectomy in differentiated thyroid cancer. Surgery 164(3):504–510PubMedCrossRef Cheng SP, Chien MN, Wang TY, Lee JJ, Lee CC, Liu CL (2018) Reconsideration of tumor size threshold for total thyroidectomy in differentiated thyroid cancer. Surgery 164(3):504–510PubMedCrossRef
10.
go back to reference Kim BW, Yousman W, Wong WX, Cheng C, McAninch EA (2016) Less is more: comparing the 2015 and 2009 American Thyroid Association Guidelines for Thyroid Nodules and Cancer. Thyroid 26(6):759–764PubMedCrossRef Kim BW, Yousman W, Wong WX, Cheng C, McAninch EA (2016) Less is more: comparing the 2015 and 2009 American Thyroid Association Guidelines for Thyroid Nodules and Cancer. Thyroid 26(6):759–764PubMedCrossRef
11.
go back to reference Frangos S, Lakovou IP, Marlowe RJ, Eftychiou N, Patsali L, Vanezi A, Savva A, Mpalaris V, Giannoula EI (2017) Acknowledging gray areas: 2015 versus 2009 American Thyroid Association differentiated thyroid cancer guidelines on ablating putatively low-intermediate-risk patients. Eur J Nucl Med Mol Imaging 44(2): 185–189PubMedCrossRef Frangos S, Lakovou IP, Marlowe RJ, Eftychiou N, Patsali L, Vanezi A, Savva A, Mpalaris V, Giannoula EI (2017) Acknowledging gray areas: 2015 versus 2009 American Thyroid Association differentiated thyroid cancer guidelines on ablating putatively low-intermediate-risk patients. Eur J Nucl Med Mol Imaging 44(2): 185–189PubMedCrossRef
12.
go back to reference Haugen BR (2015) American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: What is new and what has changed? Cancer 123(3):372–381CrossRef Haugen BR (2015) American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: What is new and what has changed? Cancer 123(3):372–381CrossRef
13.
go back to reference Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Sturgeon C (2007) Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 246(3):375–381; discussion 381–384 PubMedPubMedCentralCrossRef Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Sturgeon C (2007) Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 246(3):375–381; discussion 381–384 PubMedPubMedCentralCrossRef
14.
go back to reference Adam MA, Goffredo P, Youngwirth L, Scheri RP, Roman SA, Sosa JA (2016) Same thyroid cancer, different national practice guidelines: When discordant American Thyroid Association and National Comprehensive Cancer Network surgery recommendations are associated with compromised patient outcome. Surgery 159(1):41–50PubMedCrossRef Adam MA, Goffredo P, Youngwirth L, Scheri RP, Roman SA, Sosa JA (2016) Same thyroid cancer, different national practice guidelines: When discordant American Thyroid Association and National Comprehensive Cancer Network surgery recommendations are associated with compromised patient outcome. Surgery 159(1):41–50PubMedCrossRef
15.
go back to reference Nixon IJ, Simo R, Newbold K, Rinaldo A, Suarez C, Kowalski LP, Silver C, Shah JP, Ferlito A (2016) Management of invasive differentiated thyroid cancer. Thyroid 26(9):1156–1166PubMedPubMedCentralCrossRef Nixon IJ, Simo R, Newbold K, Rinaldo A, Suarez C, Kowalski LP, Silver C, Shah JP, Ferlito A (2016) Management of invasive differentiated thyroid cancer. Thyroid 26(9):1156–1166PubMedPubMedCentralCrossRef
16.
go back to reference Lee DY, Seok J, Jeong WJ, Ahn SH (2015) Prediction of thyroid hormone supplementation after thyroid lobectomy. J Surg Res 193(1):273–278PubMedCrossRef Lee DY, Seok J, Jeong WJ, Ahn SH (2015) Prediction of thyroid hormone supplementation after thyroid lobectomy. J Surg Res 193(1):273–278PubMedCrossRef
17.
go back to reference Jin J, Allemang MT, McHenry CR (2013) Levothyroxine replacement dosage determination after thyroidectomy. Am J Surg 205(3):360–363; discussion 363–364 PubMedCrossRef Jin J, Allemang MT, McHenry CR (2013) Levothyroxine replacement dosage determination after thyroidectomy. Am J Surg 205(3):360–363; discussion 363–364 PubMedCrossRef
18.
go back to reference Wartofsky L, Dickey RA (2005) The evidence for a narrower thyrotropin reference range is compelling. J Clin Endocrinol Metab 90:5483–5488PubMedCrossRef Wartofsky L, Dickey RA (2005) The evidence for a narrower thyrotropin reference range is compelling. J Clin Endocrinol Metab 90:5483–5488PubMedCrossRef
20.
go back to reference Razvia S, Hostalekb U (2019) Therapeutic challenges in the application of serum thyroid stimulating hormone testing in the management of patients with hypothyroidism on replacement thyroid hormone therapy: a review. Curr Med Res Opin 35(7):1215–1220CrossRef Razvia S, Hostalekb U (2019) Therapeutic challenges in the application of serum thyroid stimulating hormone testing in the management of patients with hypothyroidism on replacement thyroid hormone therapy: a review. Curr Med Res Opin 35(7):1215–1220CrossRef
21.
go back to reference Mallick U, Harmer C, Hackshaw A (2008) The HiLo trial: a multicentre randomised trial of high-versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer. Clin Oncol (R Coll Radiol) 20(5):325–356CrossRef Mallick U, Harmer C, Hackshaw A (2008) The HiLo trial: a multicentre randomised trial of high-versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer. Clin Oncol (R Coll Radiol) 20(5):325–356CrossRef
22.
go back to reference Leiker AJ, Yen TW, Cheung K, Evans DB, Wang TS (2013) Cost analysis of thyroid lobectomy and intraoperative frozen section versus total thyroidectomy in patients with a cytologic diagnosis of "suspicious for papillary thyroid cancer”. Surgery 154(6):1307–1313; discussion 1313–1314 PubMedCrossRef Leiker AJ, Yen TW, Cheung K, Evans DB, Wang TS (2013) Cost analysis of thyroid lobectomy and intraoperative frozen section versus total thyroidectomy in patients with a cytologic diagnosis of "suspicious for papillary thyroid cancer”. Surgery 154(6):1307–1313; discussion 1313–1314 PubMedCrossRef
23.
go back to reference DiMarco AN, Wong MS, Jayasekara J, Cole-Clark D, Aniss A, Glover AR, Delbridge LW, Sywak MS, Sidhu SB (2019) Risk of needing completion thyroidectomy for low-risk papillary thyroid cancers treated by lobectomy. BJS Open 3(3):299–304PubMedPubMedCentral DiMarco AN, Wong MS, Jayasekara J, Cole-Clark D, Aniss A, Glover AR, Delbridge LW, Sywak MS, Sidhu SB (2019) Risk of needing completion thyroidectomy for low-risk papillary thyroid cancers treated by lobectomy. BJS Open 3(3):299–304PubMedPubMedCentral
24.
go back to reference Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R (1998) The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 228(3):320–330PubMedPubMedCentralCrossRef Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R (1998) The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 228(3):320–330PubMedPubMedCentralCrossRef
25.
go back to reference Loyo M, Tufano RP, Gourin CG (2013) National trends in thyroid surgery and the effect of volume on short-term outcomes. Laryngoscope 123(8):2056–2063PubMedCrossRef Loyo M, Tufano RP, Gourin CG (2013) National trends in thyroid surgery and the effect of volume on short-term outcomes. Laryngoscope 123(8):2056–2063PubMedCrossRef
26.
go back to reference Kandil E, Noureldine SI, Abbas A, Tufano RP (2013) The impact of surgical volume on patient outcomes following thyroid surgery. Surgery 154(6):1346–1352; discussion 1352–1353 PubMedCrossRef Kandil E, Noureldine SI, Abbas A, Tufano RP (2013) The impact of surgical volume on patient outcomes following thyroid surgery. Surgery 154(6):1346–1352; discussion 1352–1353 PubMedCrossRef
Metadata
Title
Need for Completion Thyroidectomy in Patients Undergoing Lobectomy for Indeterminate and High-Risk Nodules: Impact of Intra-Operative Findings and Final Pathology
Authors
Edwina C. Moore
Samuel Zolin
Vikram Krishnamurthy
Judy Jin
Joyce Shin
Eren Berber
Allan Siperstein
Publication date
01-02-2020
Publisher
Springer International Publishing
Published in
World Journal of Surgery / Issue 2/2020
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-019-05189-3

Other articles of this Issue 2/2020

World Journal of Surgery 2/2020 Go to the issue